Similar studies include NCT03616886 phase I/II trial testing anti-CD73, anti-PD-L1 and chemotherapy in subjects with advanced TNBC (87), NCT03611556 phase Ib/II trial testing anti-CD73 alone or combination with gemcitabine chemotherapy and anti-PD-L1 in 212 patients with metastatic PDAC, and NCT03334617 HUDSON Platform multi-arm phase II trial for NSCLC patients who previously failed anti-PD(L)1 immunotherapy. Here, NT5E is linked to non-small cell lung carcinoma.